CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $74.40.

A number of brokerages have recently commented on CRSP. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research note on Thursday, February 13th. JMP Securities reissued a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Truist Financial boosted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Finally, HC Wainwright restated a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $71,000. Sunbelt Securities Inc. increased its holdings in CRISPR Therapeutics by 108.6% during the 4th quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company's stock worth $238,000 after purchasing an additional 3,210 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of CRISPR Therapeutics by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company's stock worth $27,166,000 after purchasing an additional 13,865 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of CRISPR Therapeutics by 1.6% in the fourth quarter. Woodline Partners LP now owns 101,600 shares of the company's stock valued at $3,999,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Westwood Holdings Group Inc. boosted its position in shares of CRISPR Therapeutics by 18.1% during the fourth quarter. Westwood Holdings Group Inc. now owns 53,102 shares of the company's stock valued at $2,090,000 after buying an additional 8,120 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded up $0.83 during midday trading on Friday, hitting $53.05. 4,410,088 shares of the company traded hands, compared to its average volume of 2,383,637. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of -12.14 and a beta of 1.67. The firm's fifty day moving average price is $41.89 and its 200-day moving average price is $45.98. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts forecast that CRISPR Therapeutics will post -5.04 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.